Although more long‐term randomized trials are needed to determine the long‐term effects of SGLT2 inhibitors as adjuvant therapy in the treatment of diabetic dogs, this study will serve as the reference for the application of SGLT2 inhibitors in dogs with T1DM. The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.